SCHEMBL17554156

SCHEMBL17554156

COc1cccc(C(=O)NCCN2CCOCC2)c1NC(=O)c1ccc(F)cc1

nearest known ligand 0.79

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BCL3 P20749 6/20 0.79
ALDH1A1 P00352 3/20 0.63
GAA P10253 1/20 0.63
CD274 Q9NZQ7 2/20 0.61
EPHX2 P34913 1/20 0.59
HTR1A P08908 1/20 0.56
DRD2 P14416 1/20 0.56
LMNA P02545 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.55
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 2/20 0.54
KMT2A Q03164 2/20 0.54
MEN1 O00255 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17554024 0.92 ALDH1A1 (0.74) BCL3ALDH1A1GAACD274LMNA
SCHEMBL17554016 0.92 BCL3 (0.75) BCL3ALDH1A1GAACD274LMNA
SCHEMBL16431268 0.89 BCL3 (1.00) BCL3ALDH1A1GAACD274LMNA
SCHEMBL29849944 0.89 BCL3 (1.00) BCL3ALDH1A1GAACD274LMNA
SCHEMBL17554113 0.88 BCL3 (0.85) BCL3ALDH1A1GAADRD2LMNA
SCHEMBL17554134 0.87 CYP2C9 (0.74) BCL3ALDH1A1GAADRD2LMNA
SCHEMBL30560634 0.83 LMNA (0.80) BCL3ALDH1A1GAADRD2LMNA
SCHEMBL17554070 0.83 LMNA (0.80) BCL3ALDH1A1GAADRD2LMNA
SCHEMBL17554064 0.82 BCL3 (0.64) BCL3ALDH1A1GAAHTR1ADRD2
SCHEMBL29849939 0.82 BCL3 (0.82) BCL3ALDH1A1GAACD274EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3628374-B1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2023-08-30 EP disclosed
EP-3628374-B1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2023-08-30 EP disclosed
EP-3628374-A2 BCL-3 INHIBITORS University College Cardiff Consultants Limited (GB) 2020-04-01 EP disclosed
EP-3628374-A2 BCL-3 INHIBITORS University College Cardiff Consultants Limited (GB) 2020-04-01 EP disclosed
US-20190248756-A1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2019-08-15 US disclosed
US-20190248756-A1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2019-08-15 US disclosed
US-10273218-B2 BCL-3 inhibitors UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2019-04-30 US disclosed
US-10273218-B2 BCL-3 inhibitors UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2019-04-30 US disclosed
US-20170267653-A1 BCL-3 INHIBITORS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2017-09-21 US disclosed
US-20170267653-A1 BCL-3 INHIBITORS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2017-09-21 US disclosed
EP-3174602-A2 BCL-3 INHIBITORS University College Cardiff Consultants Limited (GB) 2017-06-07 EP disclosed
WO-2016016728-A2 BCL-3 INHIBITORS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2016-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248756-A1 BCL-3 INHIBITORS BCL3, BCL2, BCL2L13 BCL3 1/4885ALDH1A1 2635/4885GAA 4322/4885
US-10273218-B2 BCL-3 inhibitors BCL3, BCL2, BCL2L13 BCL3 1/4885ALDH1A1 2830/4885GAA 4220/4885
US-20170267653-A1 BCL-3 INHIBITORS BCL3, BCL2, BCL2L13 BCL3 1/4885ALDH1A1 2830/4885GAA 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.